# Endovascular Debranching Early IDE Results

Patrick W. Kelly, MD, FACS

#### SANF SRD°

**Vascular Innovations** 

## Disclosures

- US Patent and Applications Pending:
  - U.S. Pat. App. No. 13706036 Debranching Stent Graft Limb and Methods for Use
  - U.S. Pat. App. No. 13706086 Visceral Double-Barreled Main Body Stent Graft and Methods for Use
  - U.S. Pat. App. No. 13706127 Debranching Visceral Stent Graft and Methods for Use
  - U.S. Pat. App. No. 13706144 Aortic Arch Double-Barreled Main Body Stent Graft and Methods for Use
  - U.S. Pat. App. No. 13706158 Debranching Great Vessel Stent Graft and Methods for Use
  - U.S. Pat. App. No. 13706175 Combination Double-Barreled and Debranching Stent Grafts and Methods for Use
  - U.S. Pat. App. No. 61740161 Stent Deployment Device
- License Agreement With MDT

#### Disclaimer

*This Presentation discusses the use of an investigational device under PSIDE G140207.* 

Current Endo Solutions Either Approved or Under Industry Sponsored Study

• T-Branch Approved in Europe and undergoing clinical trial in the U.S.

#### Z-Fem

4 fenestrations currently undergoing clinical trail in the U.S.

#### Tambe

Current going through EFS.



# All Cover The Visceral Segment During Placement Of Bridging Stents



What About This





SANF ()RD

# **Design Requirements**

- Durably exclude the aneurysm with fixation and seal
- Handle virtually any anatomy
- Provide favorable flow characteristics
- Provide unimpeded flow to vital organs throughout the surgery
- Stageable
- Be a fully OFF THE SHELF product

# Partnering With Industry



# Valiant ThoracoAbdominal Aortic Aneurysm Stent Graft System





# Thoracic Bifurcated Graft (TBG)





Proposed TBG Devices

#### Valiant Main Component

Diameter Size Match ~

#### **Endurant Extension**

20mm Limb —

16mm Limb

# Visceral Manifold (VM)



Visceral Manifold (VM)

24mm Main Body 14mm Proximal Limbs – 8mm Individual Limbs –

# Assembled System





# Proximal Deployment ike The Native Vesse Endo-Bypase 0 LOOK Like The Native Vesse Delayed Has To Seal Who Said II Has To Seal

# ThoracoaAbdominal Aortic Aneurysm Repair

Proximal Deployment Endo-Bypasses Delayed Distal Seal





# **Proximal Deployment**

# Place the Thoracic Bifurcated Graft and Visceral Manifold above the "branch vessels."

This allows for continued perfusion throughout the procedure.



#### **Proximal Deployment** Of Thoracic Bifurcated Graft





#### **Proximal Deployment** Of Visceral Manifold





# Endo-Bypass

Each of the branch vessels are stented individually from a position more proximally.

These bridging stents are slightly longer, but the favorable flow characteristics and conformability to anatomic variations mirror many of the lessons we've learned from open bypass.

















# **Delayed Distal Seal**

Once flow has been secured to each of the involved branches, then the open limb of the proximal compartmentalizing graft can be extended distally excluding the diseased segment of vessel.

#### **Delayed Distal Seal**





#### **Delayed Distal Seal**



SANF (IRD)





# Outflow Conditions of Each Configuration Under Steady State



SANF (IRD)

# Velocity Streamlines (steady-state condition)



#### SANF (IRD)

### Velocity Vector Profile (steady-state condition)



SANF ()RD

# 34 Total Patients Treated With Graft Modifications

Gender: 20 males 14 females

Mean Age: 72 (58-89)

Previous Aortic Surgery 14/34



# 34 Patients Treated

- 30 TAAA
  - 25 NonEmergent
    - 23 TBG/VM
    - 2 VM systems
  - 5 TAAA after TBD
    - 5 TBG/VM
- 1 Outlier Configuration
- 3 Emergent Leaking
  - 1 TBG/VM
  - 2 Modified Configurations

#### Intra-Op All 34 Patients

- ASA Score 4 or greater
- Length of Surgery
- Fluoro Time
- Total Contrast Used
- Target Vessels Debranched

\*3 vessels were unsuccessfully debranched secondary to previously placed suprarenal fixated stent grafts

14/34 366min (198-499) 108.3min (52-239) 177.3ml (87-357) 125/128\*

#### In Hospital Post-Op Results All 34 Patients

- Mortality rate
- MI
- Renal Failure
- CVA
- Paraplegia
- LOS
- Discharged to Home

1/34 1/345/340/343/348.4 days (3-26) 21/34 w/ LOS 5.3 days

#### Mid-term Follow-up All 34 Patients

30 Day Mortality 2/34 Both rupture patients **1yr All Cause Mortality** 12/341 at 19 months **Device Related Death Renal Failure** 0 new cases Paraplegia 0 new cases EndoLeaks 7 Total 5-Type 2 & 2- Type 3 Both T-3 Resolved – One Required Coil Intervention No Evidence of Graft Migration **Branch Graft Patency** 122/125 97%+ > 1yr

SANF BRD

#### Clinical Results Summarized All 34 Patients

•	In Hospital Mortality	1/34
•	30 Day Mortality	2/34
•	Aneurysm Related Mortality	2/34
•	1yr All Cause Mortality	12/34
•	Late Device Related Mortality	1/34 at 19mo
•	Renal Failure	5/34
•	Paraplegia	3/34
•	Patency Rates	122/125
•	Secondary Interventions	1/122 EndoBypasses



# **| & ||**

10/34 5.1-7.2 cm

#### 10/34 5.2-9.6 cm

13/34 5.0-12.1 cm

1/34 5.3 cm

\/





# **| & ||**

10/34 5.1-7.2 cm



5.2-9.6 cm

13/34 5.1-12.1 cm

1/34 5.3cm

# Conclusions





#### SANF SRD

## By approaching this problem from a non-anatomical standpoint

Of

Proximal Deployment Endo-Bypass Delayed Distal Seal



We've been able to perform in-situ customized aneurysm repairs



# Handling virtually any anatomy



With very reasonable results treating one of vascular surgeries most challenging disease processes



#### SANF SRD<sup>®</sup>

Vascular Innovations